Mark Hunter, MD
Gynecologic Oncology · Columbia, MONPI 1558441725
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $3,500 of the $5,793 with a category attached, or 60.4%. Clovis Oncology, Inc. accounts for 90.6% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2019 at $5,471 and has fallen 98.6% since, to $75 in 2025.
Across 34 payments — averaging $170.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Clovis Oncology, Inc.$5K
- Merck$221
- AstraZeneca$110
- Genmab U.S., Inc.$65
- Intuitive Surgical$54
- Covidien LP$45
- plus $50 from 2 others
Across 1 payment — averaging $14,338 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$14K
What the payments were for
- Consulting fees$3,50060%
- Speaking & faculty fees$1,00017%
- Travel & lodging$4708%
- Food & beverage$81014%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Clovis Oncology, Inc. | 9 | $5,248 |
| Merck | 12 | $221 |
| AstraZeneca | 3 | $110 |
| Genmab U.S., Inc. | 3 | $65 |
| Intuitive Surgical | 2 | $54 |
| Covidien LP | 2 | $45 |
| Johnson & Johnson | 2 | $27 |
| Boston Scientific | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Rubraca$5,235
How this compares
$5,793 in reported general payments places this provider in the 65th percentile of 38 gynecologic oncology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other gynecologic oncology in Columbia
- Sara CrowderColumbia$69K
- Arwa MohammadColumbia$2K
- Erin TullerColumbia$614
- Kristopher LybargerKansas City$743K
- Premal ThakerSaint Louis$287K
- Matthew PowellSaint Louis$162K
- David MutchSaint Louis$26K
- Dan-Arin SilasiSaint Louis$23K
- Dineo KhabeleSaint Louis$22K
- Carolyn McCourtSaint Louis$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.